1C31 nanoparticles
The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL 5 KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC) 13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 μm.
1. Pharmaceutical composition in an aqueous mixture form comprising a peptide with the amino acid sequence KLKL 5 KLK (SEQ ID NO:1) and an oligodeoxynucleotide with the nucleic acid sequence (dIdC) 13 (SEQ ID NO:2) wherein the peptide and the oligodeoxynucleotide are present as stable complexes, characterized in that
the peptide is present at a concentration of at least 100 nmol/mL and the oligodeoxynucleotide is present at a concentration of at least 4 nmol/mL,
molar ratio of the peptide to the oligodeoxynucleotide is between 20:1 and 50:1,
mean particle size of the stable complexes comprising the peptide and the oligodeoxynucleotide is less than 1 μm,
sodium ion concentration is from 0 to 25 mM,
the composition optionally comprises Ca2+ ions, phosphate ions, citrate ions, or acetate ions at a concentration of less than 1 mM each,
the composition comprises 3 to 10 mM of Tris (Tris(hydroxymethyl)aminomethane) buffer with a pH of 6 to 7.2, 3 to 20 mM of Histidine buffer with a pH of 6 to 7, or 5 to 10 mM of ammonium bicarbonate buffer with a pH of 7 to 8,
optionally, the composition has a viscosity less than 15 cP, and
optionally, the composition is sterile.
2. Composition according to claim 1 , characterized in that the pharmaceutical composition is a vaccine and contains an antigen.
3. Composition according to claim 1 , characterized in that the pharmaceutical composition contains an antigen of a human pathogen.
4. Composition according to claim 1 , characterized in that the pharmaceutical composition contains one or more carbohydrates.
5. Composition according to claim 3 , wherein the antigen is derived from Influenza virus, Hepatitis A, B or C virus (HAV, HBV, HCV), Human Papilloma virus (HPV), Human Immunodeficiency virus (HIV), Herpes Simplex virus (HSV), Parvovirus B19, Tick Borne Encephalitis virus (TBEV), Dengue virus (DENY), Japanese Encephalitis virus (JEV), West Nile virus (WNV), Yellow Fever virus (YFV), Cytomegalovirus (CMV), Mycobacterium tuberculosis, Staphylococcus aureus, Staphylococcus epidermidis, Helicobacter pylori, Streptococcus pyogenes, Streptococcus agalactiae, Chlamydia pneumoniae, Chlamydia trachomatis, Streptococcus pneumoniae, Klebsiella pneumoniae, Neisseria meningitidis, Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, Haemophilus influenzae, Moraxella catarrhalis, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Clostridium difficile, Shigella flexneri, Campylobacter jejuni, Plasmodium falciparum, Plasmodium vivax, Aspergillus spp. or Candida albicans.
6. The pharmaceutical composition according to claim 2 , wherein the antigen is a peptide or a polypeptide.
7. The pharmaceutical composition according to claim 3 , wherein the antigen of a human pathogen is from a virus, a bacterium, a fungus or a parasite.
8. The pharmaceutical composition according to claim 7 , wherein the antigen of a human pathogen is selected from the group comprising a CD8+ CTL peptide, a CD4+ Th peptide, a polypeptide, a protein, a glycoprotein, a lipoprotein, a virus particle and a whole cell or a subunit thereof.
9. The pharmaceutical composition according to claim 4 , wherein the one or more carbohydrates are sucrose and/or sorbitol.
10. The pharmaceutical composition according to claim 1 , wherein the composition is sterilized by filtration.